The ZOCOR vs. LIPITOR Copyright 2006 Harvard Health Publications is now outdated with the release of ZOCOR released generic SIMIVASTATIN.
My question is "What do the clinical trials show for the differences between LIPITOR and ZOCOR?" My current understanding is that LIPITOR can have as much as a 30% higher success at preventing non-fatal heart attacks. This statistic (if true) would lead me to go with LIPITOR over ZOCOR / SIMIVASTATIN. Please provide some clinical research information that either confirms or denies this claim.